SCHEMBL21780658

SCHEMBL21780658

O=C(O)C(c1cc(F)ccc1C1CCOCC1)N1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.38
MAOA P21397 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CHRNB2 P17787 1/20 0.36
SLC6A2 P23975 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KDM4E B2RXH2 2/20 0.35
P4HB P07237 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
OPRL1 P41146 7/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22650291 0.82 LMNA (0.38) LMNAGAAALDH1A1CHRNB2SLC6A2
SCHEMBL21780664 0.81 LMNA (0.37) LMNAGAAALDH1A1CHRNB2SLC6A2
SCHEMBL23426235 0.76 FFAR4 (0.35) LMNAGAAALDH1A1CHRNB2SLC6A2
SCHEMBL21780671 0.76 FFAR4 (0.35) LMNAGAAALDH1A1CHRNB2SLC6A2
SCHEMBL21784698 0.72 LMNA (0.55) LMNAGAAALDH1A1KDM4ECYP3A4
SCHEMBL15063187 0.72 GAA (0.50) LMNAGAAALDH1A1CHRNB2SLC6A2
SCHEMBL7798825 0.72 CYP3A4 (0.53) LMNAGAAALDH1A1KDM4ECYP3A4
SCHEMBL19182797 0.71 LMNA (0.45) LMNAGAACHRNB2SLC6A2CHRNB4
SCHEMBL21780647 0.69 LMNA (0.43) LMNAGAAKDM4ECYP3A4
SCHEMBL5183233 0.68 ALDH1A1 (0.55) LMNAGAAALDH1A1KDM4EP4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739087-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-08-29 US disclosed
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2022-03-10 US disclosed
US-11021480-B2 Inhibiting (α-V)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-01 US disclosed
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-11-12 US disclosed
EP-3617206-A1 INTEGRIN INHIBITORS Morphic Therapeutic, Inc. (US) 2020-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV LMNA 2012/4885GAA 362/4885MAOA 4081/4885
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV LMNA 2012/4885GAA 362/4885MAOA 4081/4885
US-11021480-B2 Inhibiting (α-V)(β-6) integrin ITGB6, ITGA6, ITGAV LMNA 2251/4885GAA 333/4885MAOA 4093/4885
US-11739087-B2 Inhibiting (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV LMNA 2251/4885GAA 333/4885MAOA 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.